Meeting
2018 ASCO Annual Meeting
CD8 and PD-L1 determination in lung tumor tissue as prognostic biomarker and a predictive marker of anti PD-1 efficacy.
Authors
Jean-David Fumet
Department of Medical Oncology, Center GF Leclerc, Dijon, France
Jean-David Fumet , Corentin Richard , Fanny Ledys , Quentin Klopfenstein , Caroline Truntzer , Bruno P. Coudert , Laurent Arnould , Laure Favier , Aurelie Lagrange , Sylvain Ladoire , Pierre Saintigny , Sandra Ortiz-Cuaran , Maurice Perol , Pascal Foucher , Paul Hofman , Marius Ilie , Sandy Chevrier , Romain Boidot , Valentin Derangere , François Ghiringhelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3021)
DOI
10.1200/JCO.2018.36.15_suppl.3021
Abstract #
3021
Poster Bd #
235
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
First Author: Jeddeo Paul
First Author: Susanna Swoboda
Poster
2022 ASCO Annual Meeting
Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC).
First Author: Vincent Lacasse